Lifeng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lifeng Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jinhu Wang
Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
13 shared publications - Dongfang Lu
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Jiabin Cai
Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Children and Adolescents' Health and Diseases Hangzhou Zhejiang China
11 shared publications - Jinkai Peng
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Shouhua Zhang
Department of General Surgery, Jiangxi Provincial Children’s Hospital, The Affiliated Children’s Hospital of Nanchang Medical College, Nanchang, China
11 shared publications - Ting Tao
Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.
11 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5366
Laparoscopic Surgery for Pediatric Malignant Ovarian Germ Cell Tumors After Neoadjuvant Chemotherapy: A Single-Center Retrospective Study
Purpose: The purpose of this study was to evaluate the clinical effects and safety for cancer treatment of neoadjuvant chemotherapy (NACT) when combined with laparoscopic fertility-sparing (anatomical preservation) surgery in pediatric patients who have large malignant ovarian germ cell tumors (MOGCTs). Methods: We performed a retrospective analysis on seven young female patients with a median age of 8.8 years (range: 10 months to 13.4 years). The patients were treated between 2015 and 2023, and all of them received two to three cycles of JEB (carboplatin, etoposide, and bleomycin) regimen as NACT. After the NACT, these patients had laparoscopic (n = 7) unilateral salpingo-oophorectomy. Results: Neoadjuvant chemotherapy (NACT) achieved a median reduction in tumor volume of 91% (range: 85% to 97%). All the procedures were completed successfully and there was no need to convert to open surgery. The median operative time was 85 min (range: 70 to 120 min), and the blood loss was minimal. The median blood loss was 10 mL, with a range of 5 to 50 mL. In patients with yolk sac tumors, alpha-fetoprotein (AFP) levels returned to normal within a median of 20 days after the operation. With a median follow-up of 54 months (range: 18 to 118 months), all the patients had 100% disease-free survival. Conclusions: This study suggests that NACT combined with laparoscopic fertility-sparing (anatomical preservation) surgery may be effective and appears promising for selected pediatric patients with MOGCTs.
- 9 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5366
Open AccessLaparoscopic Surgery for Pediatric Malignant Ovarian Germ Cell Tumors After Neoadjuvant Chemotherapy: A Single-Center Retrospective Study
Purpose: The purpose of this study was to evaluate the clinical effects and safety for cancer treatment of neoadjuvant chemotherapy (NACT) when combined with laparoscopic fertility-sparing (anatomical preservation) surgery in pediatric patients who have large malignant ovarian germ cell tumors (MOGCTs). Methods: We performed a retrospective analysis on seven young female patients with a median age of 8.8 years (range: 10 months to 13.4 years). The patients were treated between 2015 and 2023, and all of them received two to three cycles of JEB (carboplatin, etoposide, and bleomycin) regimen as NACT. After the NACT, these patients had laparoscopic (n = 7) unilateral salpingo-oophorectomy. Results: Neoadjuvant chemotherapy (NACT) achieved a median reduction in tumor volume of 91% (range: 85% to 97%). All the procedures were completed successfully and there was no need to convert to open surgery. The median operative time was 85 min (range: 70 to 120 min), and the blood loss was minimal. The median blood loss was 10 mL, with a range of 5 to 50 mL. In patients with yolk sac tumors, alpha-fetoprotein (AFP) levels returned to normal within a median of 20 days after the operation. With a median follow-up of 54 months (range: 18 to 118 months), all the patients had 100% disease-free survival. Conclusions: This study suggests that NACT combined with laparoscopic fertility-sparing (anatomical preservation) surgery may be effective and appears promising for selected pediatric patients with MOGCTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CIN in plasma ctDNA predicts the high-risk group in patients with pNT. A, A Heatmap of segmental alterations in ctDNA from patients with pNT. Patient information is shown at the bottom of the panel. Scale bar represents copy-number Z-score of each segment. B, Representative genome-wide copy-number variation in a healthy child (top) and a patient with pNT (bottom). C, ROC curves illustrated the diagnostic performance of chromosomal aberrations in distinguishing between healthy controls and high-risk pNTs. AUC is shown for each chromosomal aberration. D, HRD score in different risk groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. **, P < 0.01; ****, P < 0.0001; ns, not significant. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CIN in plasma ctDNA predicts the high-risk group in patients with pNT. A, A Heatmap of segmental alterations in ctDNA from patients with pNT. Patient information is shown at the bottom of the panel. Scale bar represents copy-number Z-score of each segment. B, Representative genome-wide copy-number variation in a healthy child (top) and a patient with pNT (bottom). C, ROC curves illustrated the diagnostic performance of chromosomal aberrations in distinguishing between healthy controls and high-risk pNTs. AUC is shown for each chromosomal aberration. D, HRD score in different risk groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. **, P < 0.01; ****, P < 0.0001; ns, not significant. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S2. The characteristics of ctDNA samples from pNT patients and healthy controls.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S2. The characteristics of ctDNA samples from pNT patients and healthy controls.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Chemotherapy effectively reduces CNA burden in patients with pNT. A, Log10 of TFx values in 16 paired ctDNA samples collected before and after chemotherapy from the same patients. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. ****, P < 0.0001. B, Representative genome-wide copy-number variation in patients with pNT before (top) and after (bottom) chemotherapy.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Chemotherapy effectively reduces CNA burden in patients with pNT. A, Log10 of TFx values in 16 paired ctDNA samples collected before and after chemotherapy from the same patients. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. ****, P < 0.0001. B, Representative genome-wide copy-number variation in patients with pNT before (top) and after (bottom) chemotherapy.